We assessed the clinical utility of indium 111–labeled white blood cell scans at our tertiary referral center from 2005 to 2011. Overall, scans meaningfully impacted clinical care <50% of the time. Scan utility was greater for suspected vascular graft infections or osteomyelitis.
Keywords: leukocyte scintigraphy, nuclear imaging, prosthetic graft infection, osteomyelitis
Abstract
Background
We sought to characterize the clinical utility of indium 111 (111In)–labeled white blood cell (WBC) scans by indication, to identify patient populations who might benefit most from this imaging modality.
Methods
Medical records for all patients who underwent 111In-labeled WBC scans at our tertiary referral center from 2005 to 2011 were reviewed. Scan indication, results, and final diagnosis were assessed independently by 2 infectious disease physicians. Reviewers also categorized the clinical utility of each scan as helpful vs not helpful with diagnosis and/or management according to prespecified criteria. Cases for which clinical utility could not be determined were excluded from the utility assessment.
Results
One hundred thirty-seven scans were included in this analysis; clinical utility could be determined in 132 (96%) cases. The annual number of scans decreased throughout the study period, from 26 in 2005 to 13 in 2011. Forty-one (30%) scans were positive, and 85 (62%) patients were ultimately determined to have an infection. Of the evaluable scans, 63 (48%) scans were deemed clinically useful. Clinical utility varied by scan indication: 111In-labeled WBC scans were more helpful for indications of osteomyelitis (35/50, 70% useful) or vascular access infection (10/15, 67% useful), and less helpful for evaluation of fever of unknown origin (12/35, 34% useful).
Conclusions
111In-labeled WBC scans were useful for patient care less than half of the time at our center. Targeted ordering of these scans for indications in which they have greater utility, such as suspected osteomyelitis and vascular access infections, may optimize test utilization.
Indium 111 (111In)–labeled white blood cell (WBC) scintigraphy is an imaging modality that is used in the diagnostic evaluation of occult infections when other imaging modalities are either contraindicated or uninformative. Labeled leukocytes migrate to and accumulate at sites of inflammation, which are then visualized on nuclear imaging. 111In-labeled WBC scans detect localized inflammation, but do not clearly distinguish between infectious and noninfectious inflammatory processes [1]. 111In-labeled WBC scans have been used in the diagnostic evaluation of fever of unknown origin (FUO) [2–4], prosthetic joint infections [3], vascular graft infections [5–7], and osteomyelitis [3, 8].
Test performance characteristics are traditionally reported in terms of sensitivity, specificity, and overall diagnostic accuracy. Reported sensitivity of 111In-labeled WBC scans for the diagnosis of infectious conditions ranged from 60% to 100% and specificity ranged from 69% to 92% in several series (Table 1) [2–5, 7–9]. Furthermore, the sensitivity of 111In-labeled WBC scans for detection of chronic infections is reported to be similar to that for detection of acute infections [10].
Table 1.
Reference | Indication | Methodology | Sensitivity | Specificity |
---|---|---|---|---|
Seshadri et al (2008) [2] | FUO (n = 54) | Retrospective Gold standard: overall clinical assessment at 6 months |
0.60 | 0.71 |
Kjaer et al (2002) [4] | FUO (n = 19) | Prospective Gold standard: overall clinical assessment |
0.71 | 0.92 |
Wanahita et al (2007) [3] | Bone/joint infection (n = 145) | Retrospective Gold standard: overall clinical assessment at 6 months |
0.83 | 0.90 |
Non-specific (n = 39) | 0.81 | 0.87 | ||
Schauwecker (1989) [8] | Osteomyelitis (n = 485) | Retrospective Gold standard: overall clinical assessment |
0.81 | 0.89 |
Newman (1991) [9] | Osteomyelitis/DFU (n = 41) | Prospective Gold standard: bone biopsy and culture |
0.89 | 0.69 |
Brunner (1986) [7] | Vascular graft infection (n = 70) | Retrospective Gold standard: operative/autopsy findings |
1.00 | 0.85 |
Shahidi (2007) [5] | Vascular graft infection (n = 53) | Retrospective Gold standard: operative findings, overall clinical assessment |
0.73 | 0.87 |
Abbreviations: DFU, diabetic foot ulcer; FUO, fever of unknown origin.
111In scans are often used as adjunctive tools in cases of diagnostic uncertainty. Providers look to the results of 111In scans to inform clinical decision making. However, Wanahita et al postulated that, despite sensitivity and specificity >80%, 111In-labeled WBC scans are not accurate enough to meaningfully impact clinical care in cases of difficult clinical decisions, such as whether or not to perform a revision arthroplasty on a suspected prosthetic joint infection [3]. This assertion warrants further evaluation. In the current era where increased emphasis is placed on decreasing waste and increasing value in clinical medicine, an assessment of the clinical utility of diagnostic tests must be considered.
The purpose of this investigation was to evaluate the historical use of 111In-labeled WBC scans, and to assess the frequency with which 111In-labeled WBC scans significantly impacted clinical care at our tertiary care center.
METHODS
All patients who underwent 111In-labeled WBC scans at Duke University Hospital between January 1, 2005 and December 31, 2011 were identified via the Duke Enterprise Data Unified Content Explorer (DEDUCE), a tool utilized at our center to query multiple databases containing clinical data [11]. Patient demographic information, the clinical setting in which the scan was obtained (ie, outpatient vs inpatient), and the ordering provider and/or service were obtained utilizing this query tool. Two infectious disease physicians independently reviewed the electronic medical records of all patients who underwent 111In-labeled WBC scans and obtained the following additional data elements: clinical indication for scan, scan result, diagnosis, and scan utility.
Clinical indications for scans were determined by review of provider documentation at the time the scan was ordered. Indications were categorized as one of the following: FUO, suspected osteomyelitis, suspected prosthetic device infection (eg, prosthetic joint, pacemaker), suspected vascular access infection (eg, dialysis graft), known other infection (eg, persistent staphylococcal bacteremia), or other.
Scan result was determined from the attending radiology report. The result was defined as positive if the radiology report described a focal, nonphysiologic change (generally a focal increase) in 111In uptake that was subsequently found to be a site of infection. A scan result was defined as negative if the radiology report described no focal change in 111In uptake, or if a focal change was found that did not correspond to the site of a subsequently confirmed infection. A scan result was defined as indeterminate if nonspecific changes in 111In uptake were described, or if it was otherwise not possible to ascertain from the radiology report whether a focal increase in 111In uptake was present, suggestive of infection.
The final diagnosis was determined based on review of the comprehensive electronic medical record. Final diagnoses were categorized as infectious if the patient had clinical evidence of infection supported by appropriate microbiologic and pathologic data, noninfectious if an alternate diagnosis was made based on a combination of clinical, laboratory, and radiographic data (including, eg, follow-up with no evidence of emergent infection if antimicrobial therapy was not used), or indeterminate if a clear diagnosis was not evident after a review of all available medical records. Similar methodology using overall clinical assessment as the reference standard has been utilized previously in studies of the utility of 111In-labeled WBC scans for diagnosis of infection [2–4, 12].
Each reviewer made an independent assessment of the clinical utility of the scan. Scans were categorized as clinically useful if they definitely or possibly contributed to subsequent clinical management decisions made about the patient. They were categorized as not clinically useful if they did not contribute to the clinical management of the patient. In some cases it was impossible to determine whether the scan was helpful in patient management, and these scans were categorized as having an unclear contribution to diagnosis or management. Examples of categories of clinical utility (with illustrative quotations from the medical record) follow:
Positive scan, helpful: “Pushed surgery to remove graft in setting of persistent bacteremia.”
Positive scan, possibly helpful: “Patient with prior methicillin-sensitive Staphylococcus aureus endocarditis with scan that lit up in the brain; computed tomography and magnetic resonance imaging scans done around the same time showed enhancing lesions concerning for abscesses.”
Positive scan, not helpful: “Scan consistent with arteriovenous graft infection but surgery wouldn't remove, so prolonged antibiotics.”
Negative scan, helpful: “Disseminated Mycobacterium chelonae infection, no sign of graft infection.”
Negative scan, not helpful: “Negative scan but clinically thought to have infected graft which was removed and found to be infected.”
When independent observers disagreed on the scan result or clinical utility of the scan, the case was discussed to arrive at a consensus decision; a final consensus was reached in all cases.
Descriptive statistics were used to describe and compare characteristics of patients whose scans were clinically useful vs those whose were not. Correlation of interrater observations was assessed using the κ statistic. Sensitivity and specificity of 111In-labeled WBC scans for diagnosis of infectious conditions were determined. Cases in which there were insufficient data to make a definitive diagnosis were excluded from the analysis of test sensitivity and specificity. Data analysis was performed using SAS version 9.3 (SAS Institute).
RESULTS
One hundred thirty-seven 111In-labeled WBC scans were performed at our tertiary referral hospital during the 7-year study period. The number of scans that were performed each year decreased during the study period, from 26 scans in 2005 to 13 scans in 2011. Ninety-seven (71%) scans were performed on hospitalized patients, whereas the remaining scans were performed on outpatients. 111In-labeled WBC scans were ordered by providers in a variety of specialties and subspecialties. Seventy-four (57%) scans were ordered by internal medicine specialists or subspecialists; 46 (36%) scans were ordered by general surgeons or surgical subspecialists, including 27 (21%) scans ordered by orthopedic surgeons; and 9 scans were ordered by miscellaneous other specialists (Table 2).
Table 2.
Feature | No. (%) |
---|---|
Total scans | 137 |
Male | 60 (44) |
Race | |
White | 84 (61) |
Black | 47 (34) |
Other | 6 (4) |
Age, y, mean (SD) | 53 (17) |
Age <18 | 6 (4) |
Age >70 | 23 (17) |
Setting | |
Outpatient | 40 (29) |
Inpatient | 97 (71) |
Specialty | |
Surgery | 46 (36) |
Orthopedics | 27 (21) |
General surgery | 6 (5) |
Other subspecialty | 13 (10) |
Medicine | 74 (57) |
General medicine | 24 (19) |
Infectious diseases | 7 (5) |
Other subspecialty | 43 (33) |
Pediatrics | 6 (5) |
Other | 3 (2) |
Missing | 8 |
Scans were most commonly ordered to evaluate for osteomyelitis (n = 51 [37%]). Other scan indications included FUO (n = 37 [27%]), known other infection (n = 28 [20%]), possible vascular access infection (n = 16 [12%]), possible prosthetic device infection (n = 4 [3%]), and other (n = 1 [1%]). Ultimately, a definitive diagnosis of infection was made in 85 (62%) cases and a definitive diagnosis of a noninfectious condition was made in 32 (23%) cases. There were insufficient data to make a definitive diagnosis in 20 (15%) cases. Detailed description of scan indications, results, and final diagnoses is included in Table 3.
Table 3.
Scan Indication | Result | Utility | Final Diagnosis | No. of Cases |
---|---|---|---|---|
Suspected osteomyelitis | Positive | Useful | Skin and soft tissue infection | 2 |
Chronic osteomyelitis | ||||
Tibia/fibula/femur | 6 | |||
Foot | 2 | |||
Sternum/clavicle | 1 | |||
Pelvis | 1 | |||
Chest pain | 2 | |||
Not useful | Chronic pain after surgery | 1 | ||
Infected spinal hardware | 1 | |||
Negative | Useful | Chronic pain | 5 | |
Chronic pain after surgery | 8 | |||
Drug fever | 1 | |||
Endocarditis | 1 | |||
Septic arthritis | 1 | |||
Fracture nonunion | 4 | |||
Unknown | 1 | |||
Not useful | Skin and soft tissue infection | 1 | ||
Bacteremia | 1 | |||
Osteomyelitis | 4 | |||
Prosthetic joint infection | 1 | |||
Chronic pain after surgery | 1 | |||
Chronic mastoiditis | 3 | |||
Unknown | 2 | |||
Indeterminate | Wound infection/bacteremia | 1 | ||
Fever of unknown origin | Positive | Useful | Graft-vs-host disease | 1 |
Pneumonia | 1 | |||
Not useful | Bacteremia | 2 | ||
Disseminated infection | 1 | |||
Intra-abdominal infection | 1 | |||
Unknown | 1 | |||
Negative | Useful | Chronic pain | 1 | |
Post-op fever | 2 | |||
Graft-vs-host disease | 1 | |||
Bacteremia | 3 | |||
Rheumatologic | 2 | |||
Unknown | 1 | |||
Not useful | Pneumonia | 2 | ||
Endocarditis | 2 | |||
Postoperative fever | 2 | |||
Graft-vs-host disease | 2 | |||
Rheumatologic | 1 | |||
Thrombophlebitis | 1 | |||
Drug fever | 1 | |||
Factitious disorder | 1 | |||
Splenic abscess | 1 | |||
Unknown | 5 | |||
Indeterminate | Unknown | 2 | ||
Suspected graft infection | Positive | Useful | Vascular graft infection | 6 |
Not useful | Bacteremia, possible endocarditis | 1 | ||
Negative | Useful | Graft leak/pseudoaneurysm | 1 | |
Endocarditis | 1 | |||
Disseminated mycobacterial infection | 1 | |||
Unknown | 1 | |||
Not useful | Bacteremia | 2 | ||
Vascular graft infection | 1 | |||
Vertebral osteomyelitis | 1 | |||
Indeterminate | Bacteremia | 1 | ||
Known other infection | Positive | Useful | Prosthetic joint infection | 1 |
Brain abscess | 1 | |||
Not useful | Bacteremia | 5 | ||
Osteomyelitis | 2 | |||
Disseminated candidiasis | 1 | |||
Skin and soft tissue infection | 1 | |||
Negative | Useful | Vascular graft infection | 1 | |
Vascular device infection | 1 | |||
Not useful | Bacteremia | 7 | ||
Endocarditis | 2 | |||
Tunneled catheter infection | 2 | |||
Osteomyelitis | 2 | |||
Vascular device infection | 1 | |||
Mycotic aneurysm | 1 | |||
Possible prosthetic device infection | Negative | Useful | Aseptic prosthetic joint loosening | 1 |
Not useful | Vascular device infection | 2 | ||
Indeterminate | Painful prosthesis | 1 | ||
Other | Negative | Useful | Wound infection | 1 |
The overall sensitivity of WBC scans for diagnosing any infection was 0.43; the specificity for infection was 0.90. In addition, we also assessed the sensitivity and specificity for the 3 most common scan indications (Table 4). Overall, in our population the positive predictive value of a positive 111In-labeled WBC scan for infection was 0.92, whereas the negative predictive value of 111In-labeled WBC scans for infection was 0.37.
Table 4.
Scan Indicationa | Sensitivity | Specificity |
---|---|---|
All suspected infections | 36/83 (0.43) | 28/31 (0.90) |
Fever of unknown origin | 5/15 (0.33) | 9/10 (0.90) |
Osteomyelitis | 13/25 (0.52) | 16/18 (0.89) |
Vascular graft infection | 7/13 (0.53) | 1/1 (1.00) |
a Cases for which either test result or final diagnosis were unable to be determined were excluded from this analysis.
Interestingly, the independent reviewers disagreed regarding the scan result (positive vs negative) in 13 cases. These disagreements all related to ambiguity in the radiology reports, and were resolved after reevaluation using strict interpretations of the predefined study criteria. After initial, independent review, observers agreed on the clinical utility (helpful or not helpful) in 97 (70%) cases (κ = 0.45). The 2 observers discussed each case in which individual observations regarding clinical utility differed to determine a consensus decision. After discussion, the clinical utility could not be determined in 5 cases.
Of the 132 evaluable cases, 56 (42%) scans definitely contributed to clinical management and 7 (5%) scans possibly contributed to clinical management, although other diagnostic tests provided similar information. Thus, 63 (48%) scans were deemed clinically useful in the management of patients (Table 5). The clinical utility varied by scan result and indication for the scan. Positive scans were more often found to be clinically useful than negative scans (24/41 [59%] for positive scans vs 39/91 [43%] for negative scans). Scans were more helpful for indications of osteomyelitis (35/50, 70% useful) or vascular graft infection (10/15, 67% useful), and less helpful for evaluation of FUO (12/35, 34% useful).
Table 5.
Factor | Total | Overall Utilitya, No. (%) |
Definite Contributiona, No. (%) |
Possible Contributiona, No. (%) |
---|---|---|---|---|
All cases | 132 | 63 (48) | 56 (42) | 7 (5) |
Reason for scan | ||||
Osteomyelitis | 50 | 35 (70) | 30 (60) | 5 (10) |
FUO | 35 | 12 (34) | 11 (31) | 1 (3) |
Other known infection | 28 | 4 (14) | 3 (11) | 1 (4) |
Vascular graft infection | 15 | 10 (67) | 10 (67) | … |
Prosthetic device infection | 3 | 1 (33) | 1 (33) | … |
Other | 1 | 1 (100) | 1 (100) | … |
Scan result | ||||
Positive | 41 | 24 (59) | 17 (41) | 7 (17) |
Negative | 91 | 39 (43) | 39 (43) | … |
Final diagnosis | ||||
Infection | 83 | 30 (36) | 24 (29) | 6 (7) |
Noninfectious | 31 | 26 (84) | 25 (81) | 1 (3) |
Indeterminate | 18 | 7 (39) | 7 | … |
Abbreviations: FUO, fever of unknown origin.
a Utility determined by review of medical record by 2 independent reviewers as follows: overall utility—scans definitely or possibly contributed to the clinical management of the patient; definite contribution—scans were felt to definitely impact subsequent clinical management; possible contribution—scans may have impacted clinical management but other tests provided the same or similar information.
CONCLUSIONS
We report our academic medical center's 7-year experience of the utilization and utility of 111In-labeled WBC scans for diagnosing suspected infections. Overall, 111In-labeled WBC scan results impacted clinical care less than half of the time at our center. We believe that our findings are meaningful and must be considered by clinicians in the process of diagnostic decision making.
Our approach to this evaluation is unique, as we focused primarily on the clinical utility rather than traditional measures of diagnostic accuracy. We assert that diagnostic tests provide benefit (both to clinicians and consumers of medical care) when the results meaningfully impact subsequent clinical care. In this way, both positive and negative tests can be highly beneficial. Others have reported clinical utility of nuclear imaging tests as the proportion of tests that led to a final diagnosis. Thus, only positive tests are potentially useful by this definition of clinical utility [13, 14]. Furthermore, we distinguish clinical utility from clinical accuracy. An accurate test that does not impact clinical decision making is of little value. We suspect that similar assessments of the added value of diagnostic tests will become common as the medical community faces increasing pressures to control costs.
The utility of 111In-labeled WBC scans differed depending on the clinical indication for the scan. Scans were more helpful in the management of suspected vascular access infections and osteomyelitis than FUO. This is not unexpected, given the heterogeneity of diseases encompassed by the syndrome of FUO and the known difficulty in diagnosing the etiology of FUO even in the modern era of improved cross-sectional imaging [15]. Positive scans were more likely to be helpful than negative scans. The sensitivity of 111In-labeled WBC scans for the diagnosis of infectious conditions was <50%, which is lower than values reported by others [2, 3, 7, 8, 10]. Therefore, the decreased utility among negative scans at our center may reflect an appropriate perception by prescribing physicians of the uncertainty of negative test results.
Clear written and spoken communication between prescribing physicians and consultants is essential to medical practice. This is exemplified by our findings. Independent reviewers initially disagreed regarding the scan result in approximately 10% of cases. The disagreement was felt to relate to ambiguous wording of radiology reports. As noted above, 111In-labeled WBC scans are performed infrequently at our hospital. Inexperience by providers and interpreting radiologists may have contributed to uncertainty that led to difficulty in conveying or interpreting results. Furthermore, poor interrater agreement has been previously reported for leukocyte scintigraphy. In one study, only 65% of radiologists provided the same interpretation (high, intermediate, or low probability of infection), and an interpretation of “intermediate probability” was given nearly 20% of the time [16]. Clinical utility of any test will be influenced by the consistency and clarity with which findings are reported. A standardized way of reporting scan results (as opposed to free-text reporting) may be one way to improve the clinical utility of complex tests such as 111In-labeled WBC scans; such standardized reporting using checklists has been advocated for other radiographic studies [17].
While111In-labeled WBC scintigraphy was the most common method of nuclear imaging utilized for the detection of infection at our institution during the time of the study, other radiopharmaceuticals can be used for this purpose. Gallium 67 (67Ga) citrate accumulates in body sites due to increased vascular permeability; therefore, one advantage of gallium scans is that no ex vivo cell labeling is required. However, in practice, the utility of gallium scans is limited by their lack of specificity and requirement for waiting periods up to 72 hours between injection and imaging [1, 18]. 111In oxine and Technetium 99m (99mTc)-hexamethylpropyleneamine oxime (HMPAO) are the most common agents used to label WBCs [19]. The 2 labeling techniques have some important differences. 111In-labeling is recommended over 99mTc for imaging the urinary tract and gallbladder, because excretion of 99mTc occurs via these routes [18–20]. 111In labeling is preferred for indications of chronic osteomyelitis and FUO, whereas 99mTc labeling may play a specific role in evaluation of inflammatory bowel disease or acute soft tissue infections [19, 20]. Other radiopharmaceuticals, including cytokines and antimicrobials, have been proposed but are not available for clinical use in the United States at this time [18]. Unfortunately, no one modality performs superiorly for all clinical scenarios, and, thus, understanding the strengths and weaknesses of each can help providers pursue the test most likely to provide the greatest value.
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET), which is primarily used for localization of malignancy, has also demonstrated utility for the detection of infection or inflammation [18, 21]. In one retrospective study, FDG-PET imaging was abnormal in 15 of 35 (43%) patients with FUO, and led to the diagnosis of the etiology in 13 (37%) patients. In the same study, FDG-PET was abnormal in 38 of 55 (69%) cases of suspected localized infection or inflammation and contributed to the eventual diagnosis in 36 (65%) cases [13]. The authors reported high sensitivity (93%, 100%) and specificity (90%, 89%) of FDG-PET for the diagnosis of FUO and localized infection, respectively [13]. Pill et al prospectively compared FDG-PET to traditional methods of 99mTc bone and 111In-labeled WBC scintigraphy to differentiate aseptic loosening from periprosthetic infection in patients with painful hip prostheses [22]. FDG-PET demonstrated a sensitivity and specificity of 95% and 93%, respectively, for infection whereas the 99mTc bone scan and 111In-labeled WBC together had a sensitivity and specificity of 50% and 95%, respectively. Similarly, Seshadri et al prospectively compared FDG-PET to 111In-labeled WBC scintigraphy for the evaluation of FUO [23]. The sensitivity of FDG-PET for determining the etiology of FUO was 86% whereas the sensitivity of 111In-labeled WBC scintigraphy was only 20% [23]. Thus, FDG-PET imaging has demonstrated greater sensitivity than 111In-labeled WBC scintigraphy in small, prospective comparisons. At this time, high cost and lack of reimbursement by insurance companies for noncancer indications hinder FDG-PET's more widespread use. However, FDG-PET may eventually supplant other modalities of nuclear imaging for the diagnosis of suspected infection.
We acknowledge several limitations to the current study. First, the study was performed at a single tertiary medical center in which the utilization of 111In-labeled WBC scans was relatively infrequent. Our results may not be generalizable to other settings, especially those in which nuclear imaging studies are performed commonly or are incorporated into established diagnostic algorithms. Second, assessing the clinical utility as we have done is inherently subjective. Despite using standardized, a priori definitions of clinical utility, independent reviewers initially disagreed in a minority of cases. Furthermore, determination of utility was made by retrospective review, requiring reviewers to extrapolate cause–effect relationships from the electronic medical record. If clinicians had been interviewed in real time to assess the role of the scans in decision making, the perceived utility of the scans would possibly have been higher. However, prospective interviews may have introduced bias by impacting scan prescribing practices or subsequent patient care decisions.
In the current era of increasing emphasis on cost-conscious and accountable care, appropriate utilization of expensive and logistically challenging tests is vital. 111In-labeled WBC scans are clinically useful in a minority of cases. Targeting ordering of these scans for conditions in which they are most likely to impact clinical care, including vascular graft infections and osteomyelitis, would optimize resource utilization.
Notes
Financial support. This work was supported by the Division of Infectious Diseases at Duke University Medical Center.
Potential conflicts of interest. All authors: No potential conflicts.
References
- 1.Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis. 2001;1(5):326–333. doi: 10.1016/S1473-3099(01)00146-3. [DOI] [PubMed] [Google Scholar]
- 2.Seshadri N, Solanki CK, Balan K. Utility of 111In-labelled leucocyte scintigraphy in patients with fever of unknown origin in an era of changing disease spectrum and investigational techniques. Nucl Med Commun. 2008;29(3):277–282. doi: 10.1097/MNM.0b013e3282f3ea02. [DOI] [PubMed] [Google Scholar]
- 3.Wanahita A, Villeda C, Kutka N, et al. Diagnostic sensitivity and specificity of the radionuclide (indium)-labeled leukocyte scan. J Infect. 2007;55(3):214–219. doi: 10.1016/j.jinf.2007.04.352. [DOI] [PubMed] [Google Scholar]
- 4.Kjaer A, Lebech A-M. Diagnostic value of 111In-granulocyte scintigraphy in patients with fever of unknown origin. J Nucl Med. 2002;43(2):140–144. [PubMed] [Google Scholar]
- 5.Shahidi S, Eskil A, Lundof E, et al. Detection of abdominal aortic graft infection: comparison of magnetic resonance imaging and indium-labeled white blood cell scanning. Ann Vasc Surg. 2007;21(5):586–592. doi: 10.1016/j.avsg.2007.03.018. [DOI] [PubMed] [Google Scholar]
- 6.Spacek M, Belohlavek O, Votrubova J, et al. Diagnostics of “non-acute” vascular prosthesis infection using 18F-FDG PET/CT: our experience with 96 prostheses. Eur J Nucl Med Mol Imaging. 2009;36(5):850–858. doi: 10.1007/s00259-008-1002-z. [DOI] [PubMed] [Google Scholar]
- 7.Brunner MC, Mitchell RS, Baldwin JC, et al. Prosthetic graft infection: limitations of indium white blood cell scanning. J Vasc Surg. 1986;3(1):42–48. doi: 10.1067/mva.1986.avs0030042. [DOI] [PubMed] [Google Scholar]
- 8.Schauwecker DS. Osteomyelitis: diagnosis with In-111-labeled leukocytes. Radiology. 1989;171(1):141–146. doi: 10.1148/radiology.171.1.2928518. [DOI] [PubMed] [Google Scholar]
- 9.Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers: diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA. 1991;266(9):1246–1251. doi: 10.1001/jama.266.9.1246. [DOI] [PubMed] [Google Scholar]
- 10.Datz FL, Thorne DA. Effect of chronicity of infection on the sensitivity of the In-111-labeled leukocyte scan. AJR Am J Roentgenol. 1986;147(4):809–812. doi: 10.2214/ajr.147.4.809. [DOI] [PubMed] [Google Scholar]
- 11.Horvath MM, Winfield S, Evans S, et al. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. J Biomed Inform. 2011;44(2):266–276. doi: 10.1016/j.jbi.2010.11.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.de Kleijn EM, van Lier HJ, van der Meer JW. Fever of unknown origin (FUO). II. Diagnostic procedures in a prospective multicenter study of 167 patients. The Netherlands FUO Study Group. Medicine (Baltimore) 1997;76(6):401–414. doi: 10.1097/00005792-199711000-00003. [DOI] [PubMed] [Google Scholar]
- 13.Bleeker-Rovers CP, de Kleijn EM, Corstens FH, et al. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur J Nucl Med Mol Imaging. 2004;31(1):29–37. doi: 10.1007/s00259-003-1338-3. [DOI] [PubMed] [Google Scholar]
- 14.Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48(1):35–45. [PubMed] [Google Scholar]
- 15.Naito T, Mizooka M, Mitsumoto F, et al. Diagnostic workup for fever of unknown origin: a multicenter collaborative retrospective study. BMJ Open. 2013;3(12):e003971. doi: 10.1136/bmjopen-2013-003971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Tondeur MC, Sand A, Ham HH. Interobserver reproducibility in the interpretation of 99mTc-labelled white blood cell scintigraphic images. Nucl Med Commun. 2008;29(12):1093–1099. doi: 10.1097/MNM.0b013e328310897c. [DOI] [PubMed] [Google Scholar]
- 17.Higgins LJ, Alluwaimi F, Osgood G, et al. Avoiding miscommunication in acute musculoskeletal trauma cases: use of standardized reporting and classification schemes. Semin Musculoskelet Radiol. 2013;17(4):341–358. doi: 10.1055/s-0033-1356464. [DOI] [PubMed] [Google Scholar]
- 18.Rennen HJ, Boerman OC, Oyen WJ, et al. Imaging infection/inflammation in the new millennium. Eur J Nucl Med. 2001;28(2):241–252. doi: 10.1007/s002590000447. [DOI] [PubMed] [Google Scholar]
- 19.Love C, Palestro CJ. Radionuclide imaging of inflammation and infection in the acute care setting. Semin Nucl Med. 2013;43(2):102–113. doi: 10.1053/j.semnuclmed.2012.11.003. [DOI] [PubMed] [Google Scholar]
- 20.Hughes DK. Nuclear medicine and infection detection: the relative effectiveness of imaging with 111In-oxine-, 99mTc-HMPAO-, and 99mTc-stannous fluoride colloid-labeled leukocytes and with 67Ga-citrate. J Nucl Med Technol. 2003;31(4):196–201. quiz 3–4. [PubMed] [Google Scholar]
- 21.Balink H, Verberne HJ, Bennink RJ, et al. A rationale for the use of F18-FDG PET/CT in fever and inflammation of unknown origin. Int J Mol Imaging. 2012;2012:165080. doi: 10.1155/2012/165080. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Pill SG, Parvizi J, Tang PH, et al. Comparison of fluorodeoxyglucose positron emission tomography and (111)indium-white blood cell imaging in the diagnosis of periprosthetic infection of the hip. J Arthroplasty. 2006;21(6 suppl 2):91–97. doi: 10.1016/j.arth.2006.05.021. [DOI] [PubMed] [Google Scholar]
- 23.Seshadri N, Sonoda LI, Lever AM, et al. Superiority of 18F-FDG PET compared to 111In-labelled leucocyte scintigraphy in the evaluation of fever of unknown origin. J Infect. 2012;65(1):71–79. doi: 10.1016/j.jinf.2012.02.008. [DOI] [PubMed] [Google Scholar]